 | • レポートコード：QYR2104Z0762 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、胆管がん（胆管細胞がん）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物療法、放射線療法、手術）、用途別市場規模（肝内胆管がん、肝外胆管がん）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・胆管がん（胆管細胞がん）治療の市場動向 ・企業の競争状況、市場シェア ・胆管がん（胆管細胞がん）治療の種類別市場規模（薬物療法、放射線療法、手術） ・胆管がん（胆管細胞がん）治療の用途別市場規模（肝内胆管がん、肝外胆管がん） ・胆管がん（胆管細胞がん）治療の北米市場規模2016-2027（アメリカ、カナダ） ・胆管がん（胆管細胞がん）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・胆管がん（胆管細胞がん）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・胆管がん（胆管細胞がん）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・胆管がん（胆管細胞がん）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Accord Healthcare、Bristol-Myers Squibb Company、Celgene Corporation、Delcath Systems、Eli Lilly and Company、F. Hoffman-La Roche、Fresenius Kabi、Johnson & Johnson Services、Kyowa Hakko Kirin、Mylan、Novartis、Pfizer、Sanofi、Teva Pharmaceuticals Industries） ・結論 |
Bile duct is a network of tube that connects the liver to the gall bladder. Bile duct carries a fluid called bile which is synthesize in the liver and stored in the gall bladder. The primary function of bile is breakdown of fats during digestion. Bile duct cancer is commonly known as cholangiocarcinoma. The particular cause of bile duct cancer is unknown but few factors that are responsible for developing bile duct cancer are long-term inflammation in the liver, biliary stones, abnormalities in bile duct such as cysts, infection with liver flukes parasite that causes infection in bile duct leading to cancer, and exposure to harmful chemicals and toxins. Major symptoms associated with bile duct cancer includes jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever.
The industrialization in developing counters such as India, China, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among the industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market.
Market Analysis and Insights: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
The global Bile Duct Cancer (Cholangiocarcinoma) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market.
Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Scope and Market Size
Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Drug Therapy
Radiation Therapy
Surgery
Segment by Application
Intrahepatic Bile Duct Cancer
Extrahepatic Bile Duct Cancer
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Accord Healthcare
Bristol-Myers Squibb Company
Celgene Corporation
Delcath Systems
Eli Lilly and Company
F. Hoffman-La Roche
Fresenius Kabi
Johnson & Johnson Services
Kyowa Hakko Kirin
Delcath Systems
Eli Lilly and Company
Pfizer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Therapy
1.2.3 Radiation Therapy
1.2.4 Surgery
1.3 Market by Application
1.3.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Intrahepatic Bile Duct Cancer
1.3.3 Extrahepatic Bile Duct Cancer
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Perspective (2016-2027)
2.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Growth Trends by Regions
2.2.1 Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Bile Duct Cancer (Cholangiocarcinoma) Treatment Industry Dynamic
2.3.1 Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Trends
2.3.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Drivers
2.3.3 Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Challenges
2.3.4 Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Revenue
3.1.1 Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Revenue (2016-2021)
3.1.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue
3.4 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Concentration Ratio
3.4.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue in 2020
3.5 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players Head office and Area Served
3.6 Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Product Solution and Service
3.7 Date of Enter into Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bile Duct Cancer (Cholangiocarcinoma) Treatment Breakdown Data by Type
4.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Type (2022-2027)
5 Bile Duct Cancer (Cholangiocarcinoma) Treatment Breakdown Data by Application
5.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2016-2027)
6.2 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type
6.2.1 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021)
6.2.2 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027)
6.2.3 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2027)
6.3 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application
6.3.1 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021)
6.3.2 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027)
6.3.3 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2027)
6.4 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country
6.4.1 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021)
6.4.2 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2016-2027)
7.2 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type
7.2.1 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2027)
7.3 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application
7.3.1 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2027)
7.4 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country
7.4.1 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type
8.2.1 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application
8.3.1 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Region
8.4.1 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2016-2027)
9.2 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type
9.2.1 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2027)
9.3 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application
9.3.1 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2027)
9.4 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country
9.4.1 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type
10.2.1 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application
10.3.1 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country
10.4.1 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Accord Healthcare
11.1.1 Accord Healthcare Company Details
11.1.2 Accord Healthcare Business Overview
11.1.3 Accord Healthcare Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.1.4 Accord Healthcare Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.1.5 Accord Healthcare Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Details
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Details
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.3.4 Celgene Corporation Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.3.5 Celgene Corporation Recent Development
11.4 Delcath Systems
11.4.1 Delcath Systems Company Details
11.4.2 Delcath Systems Business Overview
11.4.3 Delcath Systems Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.4.4 Delcath Systems Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.4.5 Delcath Systems Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.5.4 Eli Lilly and Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.5.5 Eli Lilly and Company Recent Development
11.6 F. Hoffman-La Roche
11.6.1 F. Hoffman-La Roche Company Details
11.6.2 F. Hoffman-La Roche Business Overview
11.6.3 F. Hoffman-La Roche Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.6.4 F. Hoffman-La Roche Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.6.5 F. Hoffman-La Roche Recent Development
11.7 Fresenius Kabi
11.7.1 Fresenius Kabi Company Details
11.7.2 Fresenius Kabi Business Overview
11.7.3 Fresenius Kabi Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.7.4 Fresenius Kabi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.7.5 Fresenius Kabi Recent Development
11.8 Johnson & Johnson Services
11.8.1 Johnson & Johnson Services Company Details
11.8.2 Johnson & Johnson Services Business Overview
11.8.3 Johnson & Johnson Services Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.8.4 Johnson & Johnson Services Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.8.5 Johnson & Johnson Services Recent Development
11.9 Kyowa Hakko Kirin
11.9.1 Kyowa Hakko Kirin Company Details
11.9.2 Kyowa Hakko Kirin Business Overview
11.9.3 Kyowa Hakko Kirin Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.9.4 Kyowa Hakko Kirin Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.9.5 Kyowa Hakko Kirin Recent Development
11.10 Mylan
11.10.1 Mylan Company Details
11.10.2 Mylan Business Overview
11.10.3 Mylan Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.10.4 Mylan Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.10.5 Mylan Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.11.4 Novartis Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.11.5 Novartis Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Details
11.12.2 Pfizer Business Overview
11.12.3 Pfizer Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.12.4 Pfizer Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.12.5 Pfizer Recent Development
11.13 Sanofi
11.13.1 Sanofi Company Details
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.13.4 Sanofi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.13.5 Sanofi Recent Development
11.14 Teva Pharmaceuticals Industries
11.14.1 Teva Pharmaceuticals Industries Company Details
11.14.2 Teva Pharmaceuticals Industries Business Overview
11.14.3 Teva Pharmaceuticals Industries Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
11.14.4 Teva Pharmaceuticals Industries Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
11.14.5 Teva Pharmaceuticals Industries Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Therapy
Table 3. Key Players of Radiation Therapy
Table 4. Key Players of Surgery
Table 5. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions (2016-2021)
Table 9. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions (2022-2027)
Table 11. Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Trends
Table 12. Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Drivers
Table 13. Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Challenges
Table 14. Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Restraints
Table 15. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Players (2016-2021)
Table 17. Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment as of 2020)
Table 18. Ranking of Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Product Solution and Service
Table 22. Date of Enter into Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Accord Healthcare Company Details
Table 63. Accord Healthcare Business Overview
Table 64. Accord Healthcare Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 65. Accord Healthcare Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 66. Accord Healthcare Recent Development
Table 67. Bristol-Myers Squibb Company Company Details
Table 68. Bristol-Myers Squibb Company Business Overview
Table 69. Bristol-Myers Squibb Company Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 70. Bristol-Myers Squibb Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 71. Bristol-Myers Squibb Company Recent Development
Table 72. Celgene Corporation Company Details
Table 73. Celgene Corporation Business Overview
Table 74. Celgene Corporation Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 75. Celgene Corporation Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 76. Celgene Corporation Recent Development
Table 77. Delcath Systems Company Details
Table 78. Delcath Systems Business Overview
Table 79. Delcath Systems Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 80. Delcath Systems Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 81. Delcath Systems Recent Development
Table 82. Eli Lilly and Company Company Details
Table 83. Eli Lilly and Company Business Overview
Table 84. Eli Lilly and Company Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 85. Eli Lilly and Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 86. Eli Lilly and Company Recent Development
Table 87. F. Hoffman-La Roche Company Details
Table 88. F. Hoffman-La Roche Business Overview
Table 89. F. Hoffman-La Roche Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 90. F. Hoffman-La Roche Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 91. F. Hoffman-La Roche Recent Development
Table 92. Fresenius Kabi Company Details
Table 93. Fresenius Kabi Business Overview
Table 94. Fresenius Kabi Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 95. Fresenius Kabi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 96. Fresenius Kabi Recent Development
Table 97. Johnson & Johnson Services Company Details
Table 98. Johnson & Johnson Services Business Overview
Table 99. Johnson & Johnson Services Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 100. Johnson & Johnson Services Recent Development
Table 101. Kyowa Hakko Kirin Company Details
Table 102. Kyowa Hakko Kirin Business Overview
Table 103. Kyowa Hakko Kirin Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 104. Kyowa Hakko Kirin Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 105. Kyowa Hakko Kirin Recent Development
Table 106. Mylan Company Details
Table 107. Mylan Business Overview
Table 108. Mylan Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 109. Mylan Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 110. Mylan Recent Development
Table 111. Novartis Company Details
Table 112. Novartis Business Overview
Table 113. Novartis Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 114. Novartis Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 115. Novartis Recent Development
Table 116. Pfizer Company Details
Table 117. Pfizer Business Overview
Table 118. Pfizer Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 119. Pfizer Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 120. Pfizer Recent Development
Table 121. Sanofi Company Details
Table 122. Sanofi Business Overview
Table 123. Sanofi Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 124. Sanofi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 125. Sanofi Recent Development
Table 126. Teva Pharmaceuticals Industries Company Details
Table 127. Teva Pharmaceuticals Industries Business Overview
Table 128. Teva Pharmaceuticals Industries Bile Duct Cancer (Cholangiocarcinoma) Treatment Product
Table 129. Teva Pharmaceuticals Industries Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021) & (US$ Million)
Table 130. Teva Pharmaceuticals Industries Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Drug Therapy Features
Figure 3. Radiation Therapy Features
Figure 4. Surgery Features
Figure 5. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application: 2020 VS 2027
Figure 6. Intrahepatic Bile Duct Cancer Case Studies
Figure 7. Extrahepatic Bile Duct Cancer Case Studies
Figure 8. Bile Duct Cancer (Cholangiocarcinoma) Treatment Report Years Considered
Figure 9. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions: 2020 VS 2027
Figure 12. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions (2022-2027)
Figure 13. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Players in 2020
Figure 14. Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue in 2020
Figure 16. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Type (2016-2021)
Figure 17. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Type (2022-2027)
Figure 18. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2016-2027)
Figure 20. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2016-2027)
Figure 21. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Country (2016-2027)
Figure 22. United States Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2016-2027)
Figure 26. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2016-2027)
Figure 27. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Country (2016-2027)
Figure 28. Germany Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Region (2016-2027)
Figure 38. China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2016-2027)
Figure 46. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2016-2027)
Figure 47. Latin America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Country (2016-2027)
Figure 48. Mexico Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Country (2016-2027)
Figure 54. Turkey Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Accord Healthcare Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 58. Bristol-Myers Squibb Company Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 59. Celgene Corporation Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 60. Delcath Systems Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 61. Eli Lilly and Company Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 62. F. Hoffman-La Roche Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 63. Fresenius Kabi Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 64. Johnson & Johnson Services Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 65. Kyowa Hakko Kirin Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 66. Mylan Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 68. Pfizer Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 69. Sanofi Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 70. Teva Pharmaceuticals Industries Revenue Growth Rate in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
世界の胆管がん市場規模・現状・予測（2021年-2027年） Bile duct cancer or cholangiocarcinoma is a form of cancer in which epithelial cells are mutated, i.e., they show epithelial differentiation in the bile duct. It is a type of rare neoplasm. Market Analysis and Insights: Global Bile Duct Cancer Market The global Bile Duct Cancer market size is projec…- 世界の胆管がん市場 2021：企業別、地域別、種類・用途別 The Bile Duct Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, r…
- 世界の膵臓＆胆管結石管理市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Pancreatic and Bile Duct Stone Management Market The global Pancreatic and Bile Duct Stone Management market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in anal…
- 世界のエアダクトクリーニングサービス市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Air Duct Cleaning Service Market The global Air Duct Cleaning Service market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, th…
- 世界の陰茎がん治療市場規模・現状・予測（2021年-2027年） Therapy of penile cancer. Market Analysis and Insights: Global Penile Cancer Treatment Market The global Penile Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and h…